Andrew Hall
Has grant
Chief Scientific Officer and Co-Founder
United KingdomResearch Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Andrew Hall is the Chief Scientific Officer and Co-Founder of RareCan Limited in the United Kingdom. His research focuses on the role of DAPK-related proteins in cancer, particularly chronic lymphocytic leukemia. Recent publications highlight DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) as a key regulator and molecular marker in this disease.
Recent Grants
Grant: Close
Using AI to support recruitment for rare cancer clinical trials
Open Date: 2024-11-01
Close Date: 2025-04-01
Grant: Close
Translating “Translation and Diagnostics” – bridging the third translational gap
Open Date: 2016-03-01
Close Date: 2017-08-30
Grant: Close
MICA: The Newcastle Proximity Laboratory
Open Date: 2015-08-31
Close Date: 2019-12-31
Grant: Close
CCLG Tissue Bank
Open Date: 2014-04-01
Close Date: 2017-06-30
Grant: Close
Cross-centre Molecular Pathology Training- the NewBel collaboration
Open Date: 2013-10-01
Close Date: 2014-09-30
Articles (1)
Year:
2020
Collaborators (3)
Vikki Rand
Professor
Teesside University
Elaine Willmore
Newcastle University
Peixun Zhou
Teesside University
ApplyKite TwinLearns as you applyMake your next move.
Prepare your application
Review drafts before you send them.